Proteomics International Quarterly Activities Report December 2025

Abstract

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to provide the following update on its business activities for the three months to 31 December 2025 and subsequent to the period end. 

Highlights

• Appointment of new CEO and Managing Director, Mr David Morris  

• Appointment of Non-Executive Director, Ms Vicki Robinson

• Commenced a strategic and operational review

• Received $2.2 million in R&D tax incentive

• Cash outflow from operations was $182,000 for the quarter ended 31 December 2025; this includes receipt of $2,687,000 from R&D tax incentive and government grants

• Received $692,288 from the exercise of 1,384,576 options as at 29 January 2026.

• Cash position of $7.7 million as at 31 December 2025
  
  

View here: Article

For further information please contact:

David Morris 
CEO and Managing Director 
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com 

Dirk van Dissel 
Investor Relations and Corporate Advisory Candour Advisory 
T: +61 408 326 367 
E: dirk@candouradvisory.com.au